a Immunoblotting of GSDMD and GSDMD-N in BM neutrophils after treatment with IFN-γ, NS from WT mice, LS from lupus mice, or IFN-γ + LS for 12 h. b Quantitative analysis of GSDMD-N/GAPDH. c Immunoblotting of GSDMD and GSDMD-N in peripheral blood neutrophils of HV. Cells were pretreated with IFN-γ. Then the cells were added with NS form HV or LS from SLE patients for 12 h. d Quantitative analysis of GSDMD-N/GAPDH levels. e Immunoblotting for GSDMD and GSDMD-N in BM neutrophils from Caspase-1−/−, Caspase-11−/− and Caspase-1−/−Caspase-11−/− mice treated with IFN-γ + LS. f Quantitative analysis of GSDMD-N/GAPDH levels. g Immunoblotting of Serpinb1, Caspase-1, Caspase-11, and GSDMD levels in BM neutrophils treated with IFN-γ + LS, or IgG deleted LS for 12 h. h Quantitative analysis of Serpinb1, Caspase-1, Caspase-11, and GSDMD-N levels. i Immunoblotting analysis of Serpinb1, Caspase-1, Caspase-11, and GSDMD levels in WT or FcγR−/− BM neutrophils after IFN-γ + LS treatment for 12 h. j Quantitative analysis of Serpinb1, Caspase-1, and Caspase-11 levels. k Immunoblotting analysis of Serpinb1, Caspase-1, and Caspase-4 levels in neutrophils isolated from the peripheral blood of HV and SLE patients. l Quantitative analysis of Serpinb1, Caspase-1, and Caspase-4 levels. m Immunoblotting analysis of Serpinb1, Caspase-1, and Caspase-11 levels in the BM neutrophils from saline or PIL mice. n Quantitative analysis of Serpinb1, Caspase-1, and Caspase-11 levels. n = 6 mice (b, f, h, j, n) or 6 donors (d, l). The immunoblotting samples shown are from the same experiment. Two blots were processed in parallel (d, l, n). Three blots were processed in parallel (b, f, h, j). Data are shown as mean ± SD. Significance was examined by one-way ANOVA (b, f, h, j), or unpaired two-sided Student’s t test (d, l, n).